Cargando…
Induction of NEDD8-conjugating enzyme E2 UBE2F by platinum protects lung cancer cells from apoptosis and confers to platinum-insensitivity
Platinum is a widely used first-line chemotherapy in treating non-small cell lung cancer of adenocarcinoma. Unfortunately, platinum resistance leads to relapse and therapeutic failure, enabling the development of platinum-sensitization strategies to be of great clinical significance. Here, we report...
Autores principales: | Zhou, Lisha, Zhu, Jin, Chen, Wangyang, Jiang, Yanyu, Hu, Tao, Wang, Yinxia, Ye, Xiaoling, Zhan, Mengxi, Ji, Chenghao, Xu, Zhuoming, Wang, Xinran, Gu, Yuanlong, Jia, Lijun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665193/ https://www.ncbi.nlm.nih.gov/pubmed/33184273 http://dx.doi.org/10.1038/s41419-020-03184-4 |
Ejemplares similares
-
NEDD8-conjugating enzyme E2s: critical targets for cancer therapy
por: Zhou, Lisha, et al.
Publicado: (2023) -
Metronomic chemotherapy in platinum-insensitive failures and/or early failures postmultimodality management in oral cancers
por: Patil, Vijay M., et al.
Publicado: (2015) -
Epigenetic and antitumor effects of platinum(IV)-octanoato conjugates
por: Novohradsky, Vojtech, et al.
Publicado: (2017) -
NEDD8 nucleates a multivalent cullin-RING-UBE2D ubiquitin ligation assembly
por: Baek, Kheewoong, et al.
Publicado: (2020) -
Platinum
Publicado: (1860)